Eton Pharmaceuticals, Inc. – NASDAQ:ETON
Eton Pharmaceuticals stock price today
$16.2
+3.14
+24.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Eton Pharmaceuticals stock price monthly change
+282.70%
month
Eton Pharmaceuticals stock price quarterly change
+282.70%
quarter
Eton Pharmaceuticals stock price yearly change
+180.65%
year
Eton Pharmaceuticals key metrics
Market Cap | 332.13M |
Enterprise value | 83.36M |
P/E | -10.49 |
EV/Sales | 3.92 |
EV/EBITDA | -12.28 |
Price/Sales | 4.38 |
Price/Book | 7.12 |
PEG ratio | 0.02 |
EPS | 0.03 |
Revenue | 34.30M |
EBITDA | 2.07M |
Income | 913K |
Revenue Q/Q | 50.18% |
Revenue Y/Y | 40.71% |
Profit margin | -42.45% |
Oper. margin | -38.87% |
Gross margin | 67.99% |
EBIT margin | -38.87% |
EBITDA margin | 6.04% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEton Pharmaceuticals stock price history
Eton Pharmaceuticals stock forecast
Eton Pharmaceuticals financial statements
Average Price Target
$13
Potential downside: -19.75%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 11.99M | 4.55M | 38% |
|---|---|---|---|
| Sep 2023 | 7.02M | -579K | -8.24% |
| Dec 2023 | 7.31M | -2.25M | -30.85% |
| Mar 2024 | 7.96M | -811K | -10.18% |
| 2024-03-14 | -0.04 | -0.09 |
|---|---|---|
| 2024-05-09 | -0.07 | -0.03 |
| Jun 2023 | 30932000 | 14.20M | 45.93% |
|---|---|---|---|
| Sep 2023 | 31526000 | 14.63M | 46.42% |
| Dec 2023 | 31740000 | 16.26M | 51.24% |
| Mar 2024 | 30794000 | 15.3M | 49.69% |
| Jun 2023 | 7.10M | 0 | -246K |
|---|---|---|---|
| Sep 2023 | 873K | 0 | -368K |
| Dec 2023 | 387K | -775K | -294K |
| Mar 2024 | -2.47M | -1.88M | -378K |
Eton Pharmaceuticals alternative data
| Sep 2023 | 28 |
|---|---|
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 28 |
| Jan 2024 | 28 |
| Feb 2024 | 28 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 28 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Eton Pharmaceuticals other data
14.68%
-8.73%
of ETON is owned by hedge funds
3.72M
-2.21M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2024 | 107500 | 0 |
| Oct 2024 | 72070 | 0 |
| Patent |
|---|
Application Filling date: 7 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 20 Jun 2018 Issue date: 26 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Sean E. Brynjelsen (1972) Pres, Chief Executive Officer & Director | $705,930 |
Mr. W. Wilson Troutman CPA (1954) Chief Financial Officer, Treasurer & Sec. | $396,480 |
Eton Pharma Near Term Catalysts Vanish
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Eton Pharmaceuticals: Fading The Rally
Volume Breakout Report Update: Buy Eton Pharmaceuticals
Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio
Harrow Health: Profitable Ophthalmic Business With Growth Potential
-
What's the price of Eton Pharmaceuticals stock today?
One share of Eton Pharmaceuticals stock can currently be purchased for approximately $16.2.
-
When is Eton Pharmaceuticals's next earnings date?
Unfortunately, Eton Pharmaceuticals's (ETON) next earnings date is currently unknown.
-
Does Eton Pharmaceuticals pay dividends?
No, Eton Pharmaceuticals does not pay dividends.
-
How much money does Eton Pharmaceuticals make?
Eton Pharmaceuticals has a market capitalization of 332.13M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 48.9% to 31.64M US dollars. Eton Pharmaceuticals made a loss 936K US dollars in net income (profit) last year or -$0.03 on an earnings per share basis.
-
What is Eton Pharmaceuticals's stock symbol?
Eton Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ETON".
-
What is Eton Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eton Pharmaceuticals?
Shares of Eton Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eton Pharmaceuticals's key executives?
Eton Pharmaceuticals's management team includes the following people:
- Mr. Sean E. Brynjelsen Pres, Chief Executive Officer & Director(age: 53, pay: $705,930)
- Mr. W. Wilson Troutman CPA Chief Financial Officer, Treasurer & Sec.(age: 71, pay: $396,480)
-
How many employees does Eton Pharmaceuticals have?
As Jul 2024, Eton Pharmaceuticals employs 30 workers, which is 7% more then previous quarter.
-
When Eton Pharmaceuticals went public?
Eton Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 13 Nov 2018.
-
What is Eton Pharmaceuticals's official website?
The official website for Eton Pharmaceuticals is etonpharma.com.
-
Where are Eton Pharmaceuticals's headquarters?
Eton Pharmaceuticals is headquartered at 21925 West Field Parkway, Deer Park, IL.
-
How can i contact Eton Pharmaceuticals?
Eton Pharmaceuticals's mailing address is 21925 West Field Parkway, Deer Park, IL and company can be reached via phone at +84 77877361.
-
What is Eton Pharmaceuticals stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Eton Pharmaceuticals in the last 12 months, the avarage price target is $13. The average price target represents a -19.75% change from the last price of $16.2.
Eton Pharmaceuticals company profile:
Eton Pharmaceuticals, Inc.
etonpharma.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
21925 West Field Parkway
Deer Park, IL 60010-7208
Deer Park, IL 60010-7208
CIK: 0001710340
ISIN: US29772L1089
CUSIP: 29772L108
